Trium Capital’s SpringWorks Therapeutics SWTX Stock Holding History

Trium Capital’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-787,459	Closed	-$37M	–	71
2025 Q2	$37M	Buy	+787,459	New	+$35M	9.21%	2

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Trium Capital's SWTX Position: Q3 2025 in Review

Trium Capital sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 787,459 shares — an estimated $37M sold.

Trium Capital first reported a position in SWTX in Q2 2025 and held it in 1 quarter. The position peaked at $37M in Q2 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

Trium Capital reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
Trium Capital sold 787,459 SpringWorks Therapeutics shares in Q3 2025, an estimated $37M.
Trium Capital first reported a position in SpringWorks Therapeutics in Q2 2025 and held it in 1 quarter.
Trium Capital's SpringWorks Therapeutics position peaked at $37M in Q2 2025.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Trium Capital's 13F filing for Q3 2025, filed 16 Oct 2025.